EFPIA, the voice of the
research-based pharmaceutical industry in Europe, welcomes the launch of the
European Commission’s new Framework for Research and Innovation: Horizon 2020. The European
Commission’s proposed €80 billion programme for investment in research and
innovation.
Commenting on last week’s announcement, Richard
Bergström, Director General of EFPIA, said: “The European Commission should be
commended for their intention to further develop public-private partnerships
(PPP). There is shared understanding that private companies and public bodies
must collaborate more and to think about new business models which allow us to
work much more quickly to meet unmet needs”.
He added: “EFPIA confirms industry interest in
continuing public private collaborations which will enable game changing
biopharmaceutical research projects that address scientific and technological
bottlenecks in areas with grand societal challenges, such as antimicrobial
resistance. Such PPPs in life sciences will clearly contribute to the three
cornerstones of the Commission proposal: Excellent
Science, Industrial Leadership and
tackling Societal Challenges.”
Mr Bergström continued: “EFPIA members are already
committed to the Innovative Medicines Initiative (IMI). In IMI the EU
Commission contributes 1 Billion Euro in cash and EFPIA member companies add an
equal 1 Billion Euro as in-kind contributions. This is a unique and first of
its kind public private partnership where cooperation between academia, SMEs
and the industry has changed the understanding and perspective of public
private partnerships within life science. There is therefore a desire to build
on the success and positive learnings from IMI to develop a new Partnership
Framework with the European Commission focused on pharmaceutical R&D. He
concluded: “We are excited about the possibility to work further with the
European Commission under Horizon 2020 - a new model for developing and sharing
knowledge”.
The project
Part of the Innovation Union,
a flagship initiative aimed at enhancing Europe’s global competitiveness,
Horizon 2020 effectively succeeds the EU’s €54.6 billion Seventh
Framework Programme for Research, Technological Development and Demonstration activities
(FP7), which runs from 2007 to 2013.
Horizon 2020, which will run
from 2014 to 2020, is a departure in that it brings together for the first time
under a single programme all of the research and innovation funding currently
provided through the Framework Programmes for Research and Technical
Development, the innovation-related activities of the Competitiveness and
Innovation Framework Programme and the European Institute of Innovation and
Technology.
It also tightens the focus on
turning scientific breakthroughs into innovative products and services, while
introducing a less complex programme architecture and cutting red tape – for
example, by simplifying reimbursement for research activities.
Funding commitments
Among the funding commitments
are a dedicated science budget of €24.6 billion, including a 77% increase in
funding for the European Research Council; and a €31.7 billion allocation to
address major concerns shared by all Europeans – one of the six ‘themes’ being
health, demographic change and well-being.
The preamble to the
Commission’s proposal for a Regulation of the European Parliament and of the
Council establishing Horizon 2020 – The Framework Programme for Research and
Innovation notes that the impact of programme funding should be maximised by
“combining Horizon 2020 and private sector funds within public-private
partnerships in key areas where research and innovation could contribute to
Europe's wider competitiveness goals and help tackle societal challenges”.
Joint Technology Initiatives.
The public-private
partnerships launched under the Seventh Framework Programme in the form of
Joint Technology Initiatives – which include the Innovative Medicines
Initiative (IMI), focused on new methods and tools to accelerate the development
of safer and more effective drugs – “may be continued using more
fit-for-purpose structures”, the preamble states.
Article 19 of the proposed
regulation proper notes that Horizon 2020 “may be implemented through
public-private partnerships where all the partners concerned commit to support
the development and implementation of research and innovation activities of
strategic importance to the Union's competitiveness and industrial leadership
or to address specific societal challenges”. The Commission’s proposal will now
be discussed by the Council and the European Parliament, with a view to
adopting the regulation before the end of 2013.
Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια
The ultimate guide for Pharma Marketing
Champions
Ζητήστε
το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…